At first glance, the measures to curb drug price increases in the Inflation Reduction Act seem like negatives for pharma and biotech stocks. If passed, as expected, Medicare (opens in new tab) would be allowed to negotiate the price it pays for a limited number of drugs. Beginning in 2026, up to 10 of Medicare’s highest-cost drugs would be included in negotiations, rising to the top 20 by 2029. In 2025, an annual $2,000 cap would be introduced on Medicare beneficiaries’ out-of-pocket prescription drug costs. But strategists at UBS Securities see some silver linings.
“We think the news is supportive,” says Mark Haefele, global wealth management chief investment officer at UBS. By reducing uncertainty and establishing a more predictable pricing outlook, the legislation could remove a long-standing overhang on the sector.
Other provisions in the bill will partially offset the negative financial impact. Expanded health-insurance subsidies that this legislation funds would enable more people to afford prescription drugs and potentially increase overall sales. And the proposal to cap out-of-pocket spending should make prescription drugs more affordable for Medicare’s high-use elderly population. Overall, according to UBS estimates, the impact equates to less than 3% of global biopharma industry earnings over a 10-year time frame.
Meanwhile, health care stocks are especially attractive now, according to UBS. Large-cap pharma companies typically offer steadily growing dividends. "We think investing in income stocks like these can help investors during an economic slowdown," says Haefele. UBS notes that during the early 2000s downturn, earnings per share for the MSCI World Index fell 50.7% peak-to-trough; dividends per share declined just 11.9%.
Because of the sector’s defensive characteristics and its ability to reduce volatility in your portfolio, UBS rates health care as “most preferred” in their global equity strategy. Other parts of the sector, such as medtech, also offer attractive long-term growth.
Anne Kates Smith brings Wall Street to Main Street, with decades of experience covering investments and personal finance for real people trying to navigate fast-changing markets, preserve financial security or plan for the future. She oversees the magazine's investing coverage, authors Kiplinger’s biannual stock-market outlooks and writes the "Your Mind and Your Money" column, a take on behavioral finance and how investors can get out of their own way. Smith began her journalism career as a writer and columnist for USA Today. Prior to joining Kiplinger, she was a senior editor at U.S. News & World Report and a contributing columnist for TheStreet. Smith is a graduate of St. John's College in Annapolis, Md., the third-oldest college in America.
Alaska Natural Disaster Victims Get Tax Relief from IRS
Upcoming tax filing and payment deadlines are extended for residents and businesses impacted by the recent storm, flooding and landslides in Alaska.
By Rocky Mengle • Published
What a Historically Low British Pound Means for Investors
The British pound sank after the U.K. government unveiled its largest set of tax cuts in decades. Here's what that means for U.S. investors.
By Will Ashworth • Published
This New Sustainable ETF’s Pitch? Give Back Profits.
investing Newday’s ETF partners with UNICEF and other groups.
By Ellen Kennedy • Published
As the Market Falls, New Retirees Need a Plan
retirement If you’re in the early stages of your retirement, you’re likely in a rough spot watching your portfolio shrink. We have some strategies to make the best of things.
By David Rodeck • Published
Where the Midterm Election Races Stand Today
Economic Forecasts In a tight race, these state elections may make the difference when midterm results are announced in November.
By Sean Lengell • Published
FedEx (FDX) Earnings Warning: Recession Harbinger or Single-Stock Hiccup?
Markets When a firm as big and broad-reaching as FedEx forecasts a sharp earnings drop, the market’s going to react. What’s this say for upcoming earnings?
By Anne Kates Smith • Published
The White House Touts A Digital Dollar: What Does That Mean?
cryptocurrency A CBDC, or Central Bank Digital Currency, is a step closer in the U.S., but going digital will take years.
By Ellen Kennedy • Published
What Ethereum's 'Merge' Means for You, the Market, and the Climate
cryptocurrency The "Merge" seems to have worked. What you need to know about crypto's biggest story of 2022.
By Rodrigo Sermeño • Published
Why a Target-Date Fund Works for Me
investing Target-date funds are attractive for their simplicity. And while I've invested in one in the past, that doesn't mean it's the right choice for you.
By Lisa Gerstner • Published
How to Spend $1,000: Find Cheap (or Free) Online Courses to Build Career Skills
Smart Buying There's a huge array of skill-building online courses that can level up your career for under $1,000.
By Kim Clark • Published